Working in collaboration with the pharmaceutical company Novartis and the contract research organisation Aprova, researchers at the Charles University in Prague conducted a 12-month patient-centred study of outcomes measurements in multiple sclerosis.
Patients completed a questionnaire assessing outcome parameters including disability progression and work capability, to assess the effectiveness of Novartis’ fingolimod (Gilenya) in the treatment of multiple sclerosis.
The rationale for the research was to provide evidence of how the drug works in a real patient population. “Real-world studies complement the pivotal randomized-controlled clinical trials conducted for approval, providing evidence on the safety and efficacy of a drug under routine clinical practice,” the study says.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
